MCA Development

MCA Development is a Dutch biotechnology company focused on the development of local immunotherapy for cancer. The company specializes in the use of Interleukin-2 (IL-2) administered directly into or near tumors to trigger a systemic immune response while minimizing toxicity. Their research covers a range of indications, including superficial bladder cancer and various skin malignancies, with significant work also conducted in the veterinary oncology space. The company's approach aims to provide a safer alternative to systemic cytokine therapy by leveraging the body's natural immune mechanisms at the site of the disease. This localized treatment strategy is designed to induce a bystander effect, potentially addressing metastatic disease through the activation of tumor-specific T cells.